Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Molecular Templates

Bristol Myers Squibb logo

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

Achieved a 53% complete response rate in study participants

Bristol Myers Squibb logo

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

Could win approval in group of rare blood cancers

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combination fails to shine in melanoma

Combo therapy did not show significant benefit in key patient population

Celgene building

UPDATED: BMS completes Celgene merger after FTC okay

Approval comes over ten months after acquisition announcement

Bristol Myers Squibb logo

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

Possible new treatment for difficult to treat cancer type

Understanding the evolving CAR-T market

In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Blue Latitude Health

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

Bristol Myers Squibb logo

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Group sales rose 6% to $6bn in the third quarter

- PMLiVE

Pfizer raises forecast following growth of biopharma business

On the flip-side company reported decline in Upjohn generics division

AstraZeneca AZ

AZ reports growth again in Q3, driven by oncology and China sales

Company has also returned to growth in Europe

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combo scores in front-line lung cancer

Makes case for duo therapy in NSCLC patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links